Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-122 + Sorafenib in Unresectable HCC
NCT02323906Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avadomide in hepatocellular carcinoma (HCC), sponsored by Celgene Corporation. Primary endpoints: Adverse Event up to 3 years and Dose-Limiting Toxicity at 28 Days. Started Jan 2015; status: terminated.
02
Drugs
avadomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02323906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323906.